BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing. Proceeds from the...